Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Aristizabal Prada ET, Weis C, Orth M, Lauseker M, Spöttl G, Maurer J, Grabowski P, Grossman A, Auernhammer CJ, Nölting S. Aristizabal Prada ET, et al. Neuroendocrinology. 2018;106(4):335-351. doi: 10.1159/000481887. Epub 2017 Oct 2. Neuroendocrinology. 2018. PMID: 28968593 Free article.
The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, Jeay S, Wuerthner JU, Aristizabal Prada ET, Spöttl G, Maurer J, Auernhammer CJ. Reuther C, et al. Among authors: aristizabal prada et. Neuroendocrinology. 2018;106(1):1-19. doi: 10.1159/000453369. Epub 2016 Nov 21. Neuroendocrinology. 2018. PMID: 27871087 Free article.
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group. Nölting S, et al. Among authors: aristizabal prada et. PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. eCollection 2017. PLoS One. 2017. PMID: 28800359 Free PMC article.
Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.
Aristizabal Prada ET, Heinzle V, Knösel T, Nölting S, Spöttl G, Maurer J, Spitzweg C, Angele M, Schmidt N, Beuschlein F, Stalla GK, Blaser R, Kuhn KA, Auernhammer CJ. Aristizabal Prada ET, et al. Endocr Relat Cancer. 2018 May;25(5):547-560. doi: 10.1530/ERC-17-0201. Epub 2018 Mar 21. Endocr Relat Cancer. 2018. PMID: 29563190
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.
Aristizabal Prada ET, Spöttl G, Maurer J, Lauseker M, Koziolek EJ, Schrader J, Grossman A, Pacak K, Beuschlein F, Auernhammer CJ, Nölting S. Aristizabal Prada ET, et al. Endocr Relat Cancer. 2018 Oct;25(10):893-908. doi: 10.1530/ERC-18-0159. Epub 2018 Jun 12. Endocr Relat Cancer. 2018. PMID: 29895527 Free PMC article.
Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures.
Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B, William D, Gieldon L, Maurer J, Spöttl G, Rank P, Knösel T, Orth M, Ziegler CG, Aristizabal Prada ET, Rubinstein G, Fassnacht M, Spitzweg C, Grossman AB, Pacak K, Beuschlein F, Bornstein SR, Eisenhofer G, Auernhammer CJ, Reincke M, Nölting S. Fankhauser M, et al. Among authors: aristizabal prada et. Endocrinology. 2019 Nov 1;160(11):2600-2617. doi: 10.1210/en.2019-00410. Endocrinology. 2019. PMID: 31322702 Free PMC article.
12 results